As of 8:10 PM 05/20/13 All times are local (Market data is delayed by at least 15 minutes).
Executive Profile*
| Age | Total Calculated Compensation | This person is connected to 68 board members in 7 different organizations across 15 different industries.
See Board Relationships |
| 55 | $382,750
|
Background*
Dr. Eric K. Rowinsky, M.D. has been Chief Medical Officer and Head of Research & Development at Stemline Therapeutics, Inc. since 2011. Dr. Rowinsky serves as Clinical Advisor of TetraLogic Pharmaceuticals, Inc. Mr. Rowinskyhas been Consultant at Coronado Biosciences, Inc. He has been the Head of Oncology Product Development of RRD International, LLC since March 2010 and oversees oncology product development. He serves as Chief Medical Officer of Champions Biotechnology, ... Inc. (now Champions Oncology, Inc.). He serves as Consultant/Scientific Advisor to multiple biotech and pharmaceutical companies in cancer drug development. He has been an Independent Consultant since January 2010. Dr. Rowinsky serves as a Scientific Advisor to ImClone Systems Corporation. He has over 25 of research and drug development experience, oncology expertise and broad scientific and medical knowledge. Dr. Rowinsky served as Executive Vice President at Stemline Therapeutics, Inc. since 2011. He served as Chief Medical Officer of ImClone Systems Corporation from February 21, 2005 to 2007 and served as its Executive Vice President from December 2007 to 2009. Dr. Rowinsky served as Senior Vice President of Clinical Research at ImClone Systems Corporation from February 21, 2005 to December 2007. He joined ImClone in 2005. He served as Chief Medical Officer of Lilly/CTRC and JHMI. From 1996 to 2010, he served as Director of the Institute of Drug Development of the Cancer Therapy and Research Center in San Antonio, Texas. He served as the SBC Endowed Chairman for Early Drug Development at the IDD of the Cancer Therapy and Research Centre in San Antonio, Texas. He served on active staff at the Johns Hopkins School of Medicine from 1987 to 1996. Dr. Rowinsky serves as the Chairman of Clinical Advisory Board at OncoVista Innovative Therapies, Inc. He serves as the Chairman of the Scientific Advisory Board of Navidea Biopharmaceuticals, Inc. He served as Chairman of Clinical Advisory Board at Aviation Upgrade Technologies Inc. He has been Vice Chairman at Coronado Biosciences, Inc. since October 2010. He has been a Director of Navidea Biopharmaceuticals, Inc since July 16, 2010 and Biogen Idec Inc. since March 2010. He serves a Director of DLVR Therapeutics Inc. He serves as a Member of Scientific Advisory Board of OncoVista Innovative Therapies, Inc. He serves on numerous scientific and oncology advisory boards for biotechnology and pharmaceutical companies. Dr. Rowinsky serves as a Member of Oncology Clinical Advisory Board at Methylgene Inc. He serves as Member of SP1049 & SP-MET-X1 Clinical Advisory Board at Supratek Pharma Inc. He served as Member of the Scientific Advisory Board of SignPath Pharma Inc. He served as a Director of Tapestry Pharmaceuticals from December 2007 to March 3, 2008 and Adventrx Pharmaceuticals Inc. from February 25, 2008 to June 15, 2011. He served as a Member of the Oncology Scientific Advisory Board at Tapestry Pharmaceuticals since April 27, 2004. Dr. Rowinsky served as a Member of Clinical Advisory Board at Point Therapeutics Inc., since June 2004. He is an Editor-in-Chief of Investigational New Drugs, and an Associate Editor of Cancer Research, Clinical Cancer Research, Annals of Oncology, and several other oncology journals. He has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. He serves on the Board of Scientific Counselors of the National Cancer Institute. He is a Member of the NCI Board of Scientific Counselors. He represented the AACR as Co-chairman of the scientific committee of the 16 th EORTC-NCI-AACR symposium on "Molecular Targets and Cancer Therapeutics," in Geneva, Switzerland. Dr. Rowinsky serves as an Adjunct Professor of Medicine at New York University School of Medicine. He served as Clinical Professor of Medicine (Division of Medical Oncology) at the University of Texas Health Science Center, San Antonio (UTHSCSA), Texas, Institute from 1996 to 2006. He was an Associate Professor of Oncology at Johns Hopkins School of Medicine from 1987 to 1996. He served on the faculty of the Department of Oncology at Johns Hopkins University School of Medicine since 1996. He was a NCI Principal Investigator on U01 anticancer drug development grants. He has done work on the development of paclitaxel, docetaxel, topotecan, irinotecan, erlotinib and gefitinib among others. Dr. Rowinsky has published over 230 papers and remains actively involved in preclinical and clinical research. Among, Dr. Rowinsky's honors include receipt of the career development award of the American Cancer Society and the 6 th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. Following his residency in Internal Medicine from University of California, San Diego, he completed fellowship training in medical oncology at the Johns Hopkins University School of Medicine. Dr. Rowinsky holds a BA degree from New York University and an MD degree from the Vanderbilt University School of Medicine.
Corporate Headquarters*
750 Lexington Avenue
New York, New York 10022
United States
Phone: 646-502-2310
Fax: --
Board Members Memberships*
Director 2007-2008 Former Director and Member of Oncology Scientific Advisory Board 2008-2011 Former Director and Member of Special Committee 2010-Present Director, Member of Science & Technology Committee and Member of Compensation & Management Development Committee 2010-Present Chairman of the Scientific Advisory Board and Director 2010-Present Vice Chairman and Consultant
Education*
BA New York University Unknown/Other Education Johns Hopkins School of Medicine Unknown/Other Education University of California - San Diego MD School of Medicine, Vanderbilt University
Other Affiliations*
|
Annual Compensation*
There is no Annual Compensation data available.
Stock Options*
There is no Stock Options data available.
Total Compensation*
| Total Annual Cash Compensation | $280,000 | | Total Calculated Compensation | $382,750 |
|
*Data is at least as current as the most recent Definitive Proxy.
